CD19 and B-cell non-Hodgkin lymphoma: In addition to axicabtagene ciloleucel and tisagenlecleucel, lisocabtagene maraleucel was tested in relapsed or refractory DLBCL, PMBCL, FL, and MCL (TRANSCEND, NCT02631044) and showed a CR rate of 80% in high-grade B-cell lymphoma (double/triple hit) and DLBCL.427,428 A phase 1 dose-escalation study (NCT03355859) of anti-CD19 JWCAR029 was conducted in refractory B-NHLs, and the ORR was 100%, with 6 of 9 (66.7%) evaluable patients achieving CR.